Enveric Biosciences, Inc.
ENVB · XNASCIK 890821fmd_08ZRX5VKBF81DK5D9YC3S23MET制造业 · 医药制剂模板: 标准
覆盖范围: 2010年1月01日 至 2026年9月30日，共 66 个期间
| 项目 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| 营业总收入 | 36 | 49 | 43 | 40 | – | – | – | – | – | – |
| 营业成本 | 29 | 38 | 34 | 32 | – | – | – | – | – | – |
| 净利息收入 | – | – | – | – | – | – | (0) | 0 | 0 | (0) |
| 毛利润 | 7 | 10 | 9 | 8 | – | – | – | – | – | – |
| 已实现投资收益（损失） | – | – | – | – | – | – | 3 | 0 | 0 | 0 |
| 研发费用 | 0 | – | – | – | 0 | 5 | 8 | 7 | 3 | 3 |
| 销售、一般及管理费用 | 9 | 19 | 11 | 2 | 5 | 20 | – | – | – | – |
| 营业费用合计 | 12 | 21 | 16 | 14 | – | – | – | – | – | – |
| 营业利润 | (5) | (11) | (7) | (2) | (6) | (65) | (27) | (16) | (10) | (9) |
| 利息费用 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | – | – | – |
| 其他营业外收入（支出） | (1) | (1) | (3) | 0 | (1) | 8 | 7 | (1) | 0 | 0 |
| 税前利润 | (7) | (11) | (11) | (5) | (7) | (56) | (20) | (17) | (10) | (9) |
| 所得税费用 | (4) | (2) | 6 | 0 | – | (7) | (1) | 0 | 0 | – |
| 持续经营净利润 | (3) | (9) | (17) | (6) | – | (49) | (18) | (17) | (10) | – |
| 净利润 | (3) | (9) | (17) | (2) | (7) | (49) | (18) | (17) | (10) | (9) |
| 归属于普通股股东的净利润 | (3) | (11) | (19) | (6) | – | (49) | (19) | (17) | (10) | (12) |